Biopharma supply chain: Balancing pressing priorities

Scroll Down

With intense pressure continuing to be placed upon the pharmaceutical industry to rapidly develop and produce vaccines and therapies to address the COVID-19 pandemic, it is imperative that biopharma supply chains adapt their practices to ensure they are robust enough to simultaneously deal with their existing workload.

In this article, Bill Vincent, chairman and CEO at Genezen, provides insight into why there is now an accelerated demand for product as a result of the COVID-19 pandemic and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.

Read the full article here: Balancing Pressing Priorities

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more